Electroporation: An avenue for transdermal drug delivery

Current Drug Delivery

Volumn 7, Issue 2, 2010, Pages 125-136

  Charoo, Naseem A ^a   Rahman, Ziyaur ^b   Repka, Michael A ^c   Murthy, S N ^c  

^a HAMDARD UNIVERSITY   (India)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Electroporation; Formulation; In vitro; In vivo; Synergism; Transdermal

Indexed keywords

BLEOMYCIN; CISPLATIN; CLONIDINE; CYCLODEXTRIN; CYCLOSPORIN A; DEXTRAN; DNA VACCINE; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FENTANYL; FLUOROURACIL; GELNIQUE; GLUCOSE; GLYCERYL TRINITRATE; GONADORELIN; INSULIN; INTERLEUKIN 12; INTERLEUKIN 2; IONTOCAINE; KERATINOCYTE GROWTH FACTOR; LIDOSITE; LIPOSOME; MELANOMA VACCINE; METHOTREXATE; METHYLPHENIDATE; MONOPHENOL MONOOXYGENASE; NALBUPHINE; NICOTINE; NONIVAMIDE; OLIGONUCLEOTIDE; OXYBUTYNIN; PARATHYROID HORMONE; PHOSPHATIDYLCHOLINE; POLYMER; PROTOPORPHYRIN; RECOMBINANT HEPATITIS B VACCINE; RIVASTIGMINE; ROTIGOTINE; SALCATONIN; SALONPAS; SELEGILINE; SULFORHODAMINE B; SYNERA; TERAZOSIN; TESTOSTERONE; TRANSDERMSCOP; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELLULAR IMMUNITY; DRUG PENETRATION; DRUG TRANSPORT; ELECTRIC POTENTIAL; ELECTROCHEMOTHERAPY; ELECTRODE; ELECTROPHORESIS; ELECTROPORATION; EMULSION; ENCAPSULATION; GENE EXPRESSION; GENE TARGETING; GENETIC CODE; HUMAN; HYDROPHILICITY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; IONTOPHORESIS; MICROELECTRODE; NONHUMAN; PAIN; PARATHYROID FUNCTION; POLARIZATION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REHYDRATION; REVIEW; SAFETY; SKIN PENETRATION; STEADY STATE; STRATUM CORNEUM; THERMAL INJURY;

EID: 77950810524     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110791011765     Document Type: Review

References (148)

1. Hadgraft, J. Passive enhancement strategies in topical and transdermal drug delivery. Int. J. Pharm., 1999, 184, 1-6. (Pubitemid 29308990)
2. Hadgraft, J.; Beutner, D.; Wolf, H.M. In-vivo-in-vitro comparisons in the transdermal delivery of nitroglycerine. Int. J. Pham., 1993, 89, R1-R4.
3. Shaw, J. Development of transdermal therapeutic systems. Drug Deliv. Ind. Pharm., 1983, 9, 19-57.
4. Kim, M.K.; Zhao, H.; Lee, C.H.; Kim, D.D. Formulation of reservoir type testosterone transdermal delivery system. Int. J. Pharm., 2001, 219, 51-59.
5. Toon, S.; Hopkins, K.J.; Aarons, L.; Rowland, M. Rate and extent of absorption of clonidine from transdermal therapeutic system. J. Pharm. Pharmacol., 1989, 41, 17-21.
6. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [accessed on September 28, 2009].
7. Hadgraft, J.; lane, M.E.; Watkinson, A.C. Dermal and Transdermal Drug Delivery. In: Modified release drug delivery technology; Informa Healthcare USA Inc: New York, 2008; pp. 268.
8. Barry, B.W. Mode of action of penetration enhancers in human skin. J. Control. Release, 1987, 6, 85-97. (Pubitemid 18017724)
9. Ghosh T.K.; Pfister T.R. Transdermal and Topical Drug Delivery Systems: An Overview and Future Trends. In: Transdermal and Topical Drug Delivery Systems; Interpharm Press: Illinois, 1997; pp. 1-25.
10. Weaver, J.C.; Vaughan, T.E.; Chizmadzhev, Y. Theory of electrical creation of aqueous pathways across skin transport barriers. Adv. Drug Deliv. Rev., 1999, 35, 21-39. (Pubitemid 29046384)
11. Mao-Qiang, M.; Feingold, K.R.; Elias, P.M. Inhibition of cholesterol and sphingolipid synthesis causes paradoxical effects on permeability barrier homeostasis. J. Invest. Dermatol., 1993, 1016, 85-90.
12. Naik, A.; Kalia, Y.N.; Guy, R.H. Transdermal drug delivery: overcoming the skin barrier function. Pharm. Sci. Technol. Today, 2000, 3, 318-320.
13. Tashiro, Y.; Kato, Y.; Hayakawa, E.; Ito, K. Iontophoretic transdermal delivery of Ketoprofen: Novel method for the evaluation of plasma drug concentration in cutaneous vein. Biol. Pharm. Bull., 2000, 23, 632-636. (Pubitemid 30321286)
14. Davis, A.; Hadgraft, J. Supersaturated Solutions as Drug Delivery Systems. In: Pharmaceutical Skin Penetration Enhancement; Marcel Dekker Inc: New York, 1993; pp. 243-267.
15. Friedman, D.I.; Schwarz, J.S.; Weisspapir, M. Submicron emulsion vehicle for enhanced transdermal delivery of steroidal and nonsteroidal anti-inflammatory drugs. J. Pharm. Sci. 1995, 84, 324-329.
16. Touiton, E.; Junginger, H.E.; Weiner, N.D.; Nagai, T.; Mezei, M. Liposomes as carriers for topical and transdermal delivery. J. Pharm. Sci., 1994, 89, 1189-1205.
17. McMahon, G.P.; O'conner, S.J.; Fitzgerald, D.J.; Roy, S.L.; Kelly, M.T. Determination of aspirin and salicylic acid in transdermal perfusates. J. Chromatogr. B, 1988, 707, 322-327.
18. Goodman, M.; Barry, B.W. Liquid protein partitioning theory of skin enhancer activity finite dose technique. Int. J. Pharm., 1989, 57, 29-40.
19. Aungst, B.J.; Blake, J.A.; Hussain, M.A. Contributions of drug solubilization, partitioning, barrier disruption and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines. Pharm. Res., 1990, 7, 712-720.
20. Michniak, B.; Player, M.R.; Chapman, J.M.; Sowell, J.W. In-vitro evaluation of a series of azone analogues as dermal penetration enhancers. Int. J. Pharm., 1993, 91, 85-93. (Pubitemid 23121404)
21. Puglia, C.; Bonina, F. Effect of polyunsaturated fatty acids and some conventional penetration enhancers on transdermal delivery of atenolol. Drug Deliv., 2008, 15, 107-112. (Pubitemid 351302235)
22. Takahashi, K.; Tamagawa, S.; Kattagi, T.; Yoshitomi, H.; Kamada, A.; Rhytting, J.; Nishihata, T.; Mizuro, N. In-vitro transport of sodium diclofenac across rat abdominal skin: effect of selection of oleaginous component and the addition of alcohols to the vehicle. Chem. Pharm. Bull., 1991, 39, 154-158.
23. Southwell, D.; Barry, B. Penetration enhancers for human skin: mode of action of 2 pyrrolidone and dimethylformamide on partition and diffusion of model compounds water, alcohols and caffeine. J. Invest. Dermatol., 1983, 66, 243-252.
24. Sasaki, H.; Kojima, M.; Mori, Y.; Nakamura, J.; Shibasaki, J. Enhancing effect of pyrrolidone derivatives on transdermal drug delivery. Int. J. Pharm., 1988, 44, 15-24.
25. Babu, R.J.; Dhanasekaran, M.; Vaithiyalingam, S.R.; Singh, P.N.; Pandit, J.K. Cardiovascular effects of transdermally delivered bupranolol in rabbits: effect of chemical penetration enhancers. Life Sci., 2008, 82, 273-278.
26. Choi, H.K.; Amidon, G.L.; Flynn, G.L. Some general influences of n-decylmethyl sulfoxide on the permeation of drugs across hairless mouse skin. J. Invest. Dermatol. 1991, 96, 822-826.
27. Palma, S.D.; Maletto, B.; Lo, Nostro, P.; Manzo, R.H.; Pistoresi-Palencia, M.C.; Allemandi, D.A. Potential use of ascorbic acidbased surfactants as skin penetration enhancers. Drug Deliv. Ind. Pharm., 2006, 32, 821-827.
28. Williams, A.C.; Barry, B.W. Terpenes and the lipid protein partitioning theory of skin penetration enhancement. Pharm. Res., 1991, 8, 17-24.
29. Becker, S.M.; Kuznetsov A.V. Thermal in vivo skin electroporation pore development and charged macromolecule transdermal delivery: A numerical study of the influence of chemically enhanced lower lipid phase transition temperatures. Int. J. Heat Mass Trans., 2008, 51, 2060-2074.
30. Pliquet, U. ; Langer, R. ; Weaver, J.C. Changes in the passive electrical properties of human stratum corneum due to electroporation. Biochem. Biophys. Acta., 1995, 1239, 111-121.
31. Treco, D.A.; Seldon, R.F.; New viral gene therapy. Mol. Med. Today, 1995, 1, 314-321.
32. Bommannan, D.; Tamada, J.; Leung, L.; Potts, R.O. Effect of electroporation on transdermal iontophoretic delivery of lutinizing hormone releasing hormone in-vitro. Pharm. Res., 1994, 11, 1809-1814. (Pubitemid 24377095)
33. Prausnitz, M,R.; Edelman, E.R.; Gimm, J.S.; Langer, R.; Weaver, J.C. Transdermal delivery of heparin by skin electroporation. Biotechnology, 1995, 13, 205-209.
34. Banga, A.K.; Bose, S.; Ghosh, T.K. Iontophoresis and electroporation: comparisons and contrasts. Int. J. Pharm., 1999, 179, 1-19.
35. Prausnitz, M.R.; Seddick, D.S.; Kon, A.A.; Bose, V.G.; Frankenburg, S.; Klaus, S.N.; Langer, R.; Weaver, J.C. Methods for in-vivo tissue electroporation using surface electrodes. Drug Deliv., 1993, 1, 125-131.
36. Fiedler, S.; Wirth, R. Transformation of bacteria with plasmid DNA by electroporation. Anal. Biochem., 1988, 170, 38-44.
37. Vanbever, R.; Lecouturier, N.; Preat, V. Transdermal delivery of metoprolol by electroporation. Pharm. Res., 1994, 11, 1657-1662.
38. Hirsch, A.C.; Upasani, R.S.; Banga, A.K. Factorial design approach to evaluate interactions between electrically assisted enhancement and skin stripping for delivery of tacrine. J. Control. Release, 2005, 103, 113-121.
39. Mir, L.M.; Gehl, J.; Sersa, G.; Collins, G.C.; Garbay, J.R.; Billard, V.; Geersten, P.F.; Rudolf, Z.; O'Sullivan, G.C.; Marty, M. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator™ by means of invasive or non-invasive electrodes. Eur. J. Cancer Suppl., 2006, 4, 14-25. (Pubitemid 44755132)
40. Golden, G.M.; McKie, J.E.; Potts, R.O. Role of stratum corneum lipid fluidity in transdermal drug flux. J. Pharm. Sci., 1987, 76, 25-28.
41. Bouwstra, J.A.; Peschier, L.J.C.; Brussee, J.; Bodde, H.E.; Effect of n-alkyl- azocycloheptan-2-ones including azone on the thermal behaviour of human stratum corneum. Int. J. Pharm., 1989, 52, 47-54.
42. Preat V, Vanbever R. Skin eletroporation for transdermal and topical drug delivery. In: Transdermal Drug Delivery; Mercer Dekker Inc: New York, 2003; pp. 227-254.
43. Regnier, V.; Preat, V. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm. Res., 1998, 15, 1596-1602. (Pubitemid 28465747)
44. Tokumoto, S.; Higo, N.; Sugibayashi, K. Effect of electroporation and pH on the iontophoretic transdermal delivery of human insulin. Int. J. Pharm., 2006, 326, 13-19. (Pubitemid 44647740)
45. Gupta, S.K.; Southam, M.; Sathyan, G.; Klausner, M. Effect of current density on pharmacokinetics following continuous or intermittent input from a fentanyl electrotransport system. J. Pharm. Sci., 1998, 87, 976-981. (Pubitemid 28381255)
46. Foldvari, M.; Babiuk, S.; Badea, I. DNA delivery for vaccination and therapeutics through the skin. Curr. Drug. Deliv., 2006, 3, 17-28.
47. Gehl, J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol. Scand., 2003, 177, 437-447.
48. Becker, S.M.; Kuznetsov, A.V. Thermal damage reduction associated with in vivo skin electroporation: A numerical investigation justifying aggressive pre-cooling. Int. J. Heat Mass Trans., 2007, 50, 105-116.
49. Wang, Y.; Thakur, R.; Fan, Q.; Michniak, B. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur. J. Pharm. Biopharm., 2005, 60, 179-191. (Pubitemid 40804560)
50. Huang, J.F.; Sung, K.C.; Hub, Y.P.; Wang, J.J.; Lin, Y.H.; Fang, J.Y. The effects of electrically assisted methods on transdermal delivery of nalbuphine benzoate and sebacoyl dinalbuphine ester from solutions and hydrogels. Int. J. Pharm., 2005, 297, 162-171.
51. Sen A.; Zhao Y.; Zhang L.; Hui S.W. Enhanced transdermal transport by electroporation using anionic Lipids. J. Control. Release, 2002, 82, 399-405. (Pubitemid 34880193)
52. Becker S.M.; Kuznetsov A.V. Numerical modeling of in vivo plate electroporation thermal dose assessment. J. Biomech. Eng., 2006, 128, 76-84.
53. Becker S.M.; Kuznetsov A.V. Local temperature rises influence in-vivo electroporation pore development: A numerical stratum corneum lipid phase transition model. J. Biomech. Eng., 2007, 129, 712-721.
54. Vanbever, R,; Le, Boulenge, E.; Preat, V. Transdermal delivery of fentanyl by electroporation I. influence of electrical factors. Pharm. Res., 1996, 13, 559-565. (Pubitemid 26119058)
55. Vanbever, R.; Pliquett, U.F.; Preat, V.; Weaver, J.C. Comparison of the effects of short, high-voltage and long, medium-voltage pulses on skin electrical and transport properties. J. Control Release, 1999, 60, 35-47.
56. Pliquett, U.F.; Zewert, T.E.; Chen, T.; Langer, R.; Weaver, J.C. Imaging of fluorescent molecule and small ion transport through human stratum corneum during high voltage pulsing: localized transport regions are involved. Biophys. Chem., 1996, 58, 185-204.
57. Sharma, A.; Kara, M.; Smith, R.; Krishnan, T.R. Transdermal drug delivery using electroporation. I. Factors influencing in-vitro delivery of terazosin hydrochloride in hairless rats. J. Pharm. Sci., 2000, 89, 528-535.
58. Weaver, J.C.; Chizmadzhev, Y.A. Electroporation. In: Handbook of Biological Effects of Electromagnetic Fields; CRC Press: New York, 1995; pp. 247-274.
59. Bernard, E.; Dobois, J.L.; Wepierre, J. Percutaneous absorption of new antiandrogen included in liposomes or in solution. Int. J. Pharm., 1995, 126, 235-243. (Pubitemid 26018579)
60. Codrech, L.; Oliva, M.; Pons, M.; Maza, A.D.; Manich, A.M.; Parra, J.L. Percutaneous penetration of liposomes using the tape stripping technique. Int. J. Pharm., 1996, 139, 197-203.
61. Puglisi, G.; Fresta, M. Application of liposomes as potential cutaneous drug delivery system: in-vitro and in-vivo investigation with radioactively labelled vesicles. J. Drug Target., 1996, 4, 95-101. (Pubitemid 26381471)
62. Essa, E.A.; Bonner, M.C.; Barry, B.W. Electroporation and ultradeformable liposomes; human skin barrier repair by phospholipids. J. Control. Release, 2003, 92, 163-172.
63. Badkar, A.V.; Betageri, G.V.; Hofmann, G.A.; Banga, A.K. Enhancement of transdermal iontophoretic delivery of a liposomal formulation of colchicine by electroporation. Drug Deliv., 1999, 6, 111-115.
64. Hofmann, G.A. Instrumentation. In: Electroporation Protocols for Microorganisms; Humana Press: Totowa, 1995; pp. 27-45.
65. Frantz, S.W. Instrumentation And Methodology For In Vitro Skin Diffusion Cells. In: Methods For Skin Absorption; CRC Press: Florida, 1990; pp. 35-59.
66. Keshary, P.R.; Chien, Y.W. Mechanism of transdermal controlled nitroglycerin administration. Part 2. Assessment of rate controlling steps. Drug Deliv. Ind. Pharm., 1984, 10, 1663-1699.
67. Glikfeld, P.; Cullander, C.; Hinz, R.S.; Guy, R.H. A new system for in-vitro studies of iontophoresis. Pharm. Res., 1988, 5, 443-446.
68. Jones, B.; Lynch, P.T.; Power, J.B.; Davey, M.R. Electrofusion And Electroporation Equipments. In: Electrical Manipulation of Cells; Chapman and Hall: London, 1996; pp. 1-14.
69. Medi, B.M.; Singh, J. Electronically facilitated transdermal delivery of human parathyroid harmone. Int. J. Pharm., 2003, 263, 25-33. (Pubitemid 37087929)
70. Murthy, S.N.; Zhao, Y.L.; Marlan, K.; Hui, S.W.; Kazim, L.A.; Sen, A. Lipid and electroosmosis enhanced transdermal delivery of insulin by electroporation. J. Pharm. Sci., 2006, 95, 2041-2050. (Pubitemid 44433033)
71. Richard, G.; Mark, J.; Richar, H. Device and method to facilitate directed delivery and electroporation. 2005, WO 2005/010161.
72. Genetronics Web site, http://www.genetronics.com (accessed on April 30, 2008)
73. Transdermal system machine to aid delivery of mesotherapy protocols - no needles required. http://www.consultdrminas.com/ index.php?cnt=3&sub= 18&trs=1 (accessed on September 28, 2009)
74. Skelly, J.P.; Shah, V.P.; Maibach, H.I.; Guy, R.H.; Wester, R.C.; Flynn, G.; Yacobi, A. FDA and AAPS report of the workshop on principles and practices of in-vitro percutaneous penetration studies: Relevance to bioavailability and bioequivalence. Pharm. Res., 1987, 4, 265-267.
75. Behl, C.R.; Kumar, S.; Malick, A.W.; Patel, S.B.; Char, H. Choice of Membranes for In Vitro Skin Uptake Studies and General Experimental Techniques. In: Methods for Skin Absorption; CRC press: Florida, 1990; pp. 1-21.
76. Catz, P.; Friend, D.R.; Heller, J. Transdermal permeation enhancers for drugs. Proc. Int. Symp. Control. Release Bioact. Mater., 1988, 15, 152-153.
77. Catz, P.; Friend, D.R. Transdermal delivery of levonorgestrel: effect of enhancers on rat skin, hairless mouse skin, hairless guinea pig skin and human skin. Int. J. Pharm., 1990, 58, 93-102.
78. Buyuktimkin, S.; Buyuktimkin, N.; Rytting, J.H. Preparation and enhancing effect of 1-(N, N-dimethylamino) 1-2 propanol dodecanoate), (DAIPD) on the transdermal penetration of clonidine hydrocortisone and indomethacin through shed skin. Int. J. Pharm., 1995, 118, 113-119.
79. Roy, S.D.; Roose, E.; Sharma, K. Transdermal delivery of buprenorphine through cadaver skin. J. Pharm. Sci., 1994, 83, 126-130. (Pubitemid 24224164)
80. Fang, J.Y.; Huang, Y.B.; Wang, H.Y.; Tsai, Y.H. Electrically-assisted skin permeation of two synthetic capsaicin derivatives, sodium nonivamide acetate and sodium nonivamide propionate, via rate-controlling polyethylene membranes. Biol. Pharm. Bull., 2005, 28, 1695-1701.
81. Smith, K.L. Penetrant Characteristics Influencing Skin Absorption. In: Methods for Skin Absorption; CRC Press: Florida, 1990; pp. 23-34.
82. Friend, D.R. In vitro permeation techniques. J. Control. Release, 1992, 18, 235-248.
83. Ortega, V.V. ; Martínez, A.F.; Gascón, J.Y. ; Sánchez, N.A.; Baños, M.A.; Rubiales, F.C. Transdermal transport of India ink by electromagnetic electroporation in Guinea pigs: an ultrastructural study. Ultrastruct. Pathol., 2006, 30, 65-74. (Pubitemid 44178573)
84. Pliquett, U. Mechanistic Studies of Molecular Transdermal Transport Due to Skin Electroporation. Adv. Drug Deliv. Rev., 1999, 35, 41-60. (Pubitemid 29046385)
85. Martin, G.T.; Pliquett, U.F.; Weaver, J.C. Theoretical analysis of localized heating in human skin subjected to high voltage pulses. Bioelectrochemistry, 2002, 57, 55-64.
86. Vanbever, R.; Préat, V. In-vivo efficacy and safety of skin electroporation. Adv. Drug Deliv. Rev., 1999, 35, 77-88. (Pubitemid 29046387)
87. Murthy, S.N.; Sen, A.; Hui, S.W. Surfactant-enhanced transdermal delivery by electroporation. J. Control. Release, 2004, 98, 307-315.
88. Tung, L.; Troiano, G.C.; Sharma, V.; Raphael, R.M.; Stebe, K.J. Changes in electroporation thresholds of lipid membranes by surfactants and peptides. Ann. N. Y. Acad. Sci., 1999, 888, 249-265.
89. Wong, T.W.; Zhao, Y.L.; Sen, A.; Hui, S.W. Pilot study of topical delivery of methotrexate by electroporation. Br. J. Dermatol., 2005, 152, 524-530. (Pubitemid 40547127)
90. Vanbever, R.; Langers, G.; Montmayeur, S.; Préat, S. Transdermal delivery of fentanyl: rapid onset of analgesia using skin electroporation. J. Control. Release, 1998, 50, 225-235.
91. Becker, S.M.; Kuznetsov, A.V. Numerical assessment of thermal response associated with in-vivo skin electroporation: the importance of the composite skin model. J. Biomech. Eng., 2007, 129, 330-340.
92. Másson, M. ; Loftsson, T. ; Másson, G. ; Stefánsson, E. Cyclodextrins as permeation enhancers: some theoretical evaluations and in-vitro testing. J. Control. Release, 1999, 59, 107-118. (Pubitemid 29187198)
93. Vitroria, M.; Bentley, L.B.; Vianna, R.F.; Wilson, S.; Collett, J.H. Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J. Pharm. Pharmacol., 1997, 49, 397-402.
94. Murthy, S.N.; Zhao, Y.L.; Sen, A.; Hui, S.W. Cyclodextrin enhanced transdermal delivery of piroxicam and carboxyfluorescein by electroporation. J. Control. Release, 2004, 99, 393-402.
95. Helena, M.; Morques, C.; Hadgraft, J.; Kellaway, I.W.; Taylor, G. Studies of cyclodextrin inclusion complexes: IV. The pulmonary absorption of salbutamol from a complex with 2 hydroxypropyl-β-cyclodextrin in rabbits. Int. J. Pharm., 1991, 77, 303-307.
96. Wong, T.W.; Chen, C.H.; Huang, C.C.; Lin, C.D.; Hui, S.W. Painless electroporation with a new needle-free microelectrode array to enhance transdermal drug delivery. J. Control. Release, 2006, 110, 557-565.
97. Tomov, T.C. Quantitative dependence of electroporation on the pulse parameters. Bioelectrochem. Bioenerg., 1995, 37, 101-107.
98. Prausnitz, M.R. Do high voltage pulses cause changes in skin structure? J. Control. Release, 1996, 40, 321-326.
99. Jadoul, A.; Regnier, V.; Doucet, J.; Durand, D.; Preat, V. X-ray scattering analysis of human stratum corneum treated by high voltage pulses. Pharm. Res., 1997, 14, 1275-1277. (Pubitemid 27432557)
100. Leo, W.R.; Shen, S.C.; Lai, H.H.; Hu, C.H.; Fungi, J.Y. Transdermal drug delivery enhanced and controlled by erbium: YAG laser, a comparative study of lipophilic and hydrophilic drugs. J. Control. Release, 2001, 75, 155-166.
101. Fang, J.Y.; Hung, C.F.; Fang, Y.P.; Chan, T.F.; Transdermal iontophoresis of 5- fluorouracil combined with electroporation and laser treatment. Int. J. Pharm., 2004, 270, 241-249.
102. Vanbever, R.; Prausnitz, M.R.; Preat, V. Macromolecules as novel transdernmal transport enhancers for skin electroporation. Pharm. Res., 1997, 14, 638-644. (Pubitemid 27220283)
103. Zewert, T.E.; Pliquett, U.F.; Vanbever, R.; Langer, R.; Weaver, J.C. Creation of transdermal pathways for macromolecule transport by skin elecroporation and a low toxicity, pathway- enlarging molecule. Bioelectrochem. Bioenerg., 1999, 49, 11-20.
104. Scholnick, M.; Hui, S.W.; Sen, A. Influence of DMPS on the water retention capacity of electroporated stratum corneum. ATR: FTIR study. Int. J. Pharm., 2007, 350, 138-144.
105. Sen, A.; Zhao, Y.L.; Hui, S.W. Saturated anionic phospholipids enhance transdermal transport by electroporation. Biophys. J., 2002, 83, 2064-2073.
106. Sen, A.; Daly, M.E.; Hui, S.W. Transdermal insulin delivery using lipid enhanced electroporation. Biochim. Biophys. Acta, 2002, 1564, 5-8. (Pubitemid 34717862)
107. Kost, J.; Pliquett, U.; Mitragotri, S.; Yamamoto, A.; Weaver, J.; Langer, R. Enhanced transdermal delivery; synergistic effect of ultrasound and electroporation. Pharm. Res., 1996, 13, 633-638. (Pubitemid 26119070)
108. Prausnitz, M.R.; Bose, V.; Langer, R.; Weaver, J.C. Electroporation of a mammalian skin: A mechanism to enhance transdermal drug delivery. Proc. Natl. Acad. Sci. USA, 1993, 90, 10504-10508.
109. Vogel, J.C. Nonviral skin gene therapy. Hum. Gene Ther., 2000, 11, 2253-2259.
110. Barron, L.G.; Gagne, L. ; Szoka, F.C. Lipoplex-mediated gene delivery to the lung occurs within 60 minutes of intravenous administration. Hum. Gene Ther., 1999, 10, 1683-1694
111. Birchall, J.C.; Waterworth, C.A,; Luscombe, C.; Parkins, D.A.; Gumbleton, M.J. Statistical modelling of the formulation variables in non-viral gene delivery systems. J. Drug Target, 2001, 9, 169-184.
112. Babiuk, S.; Baca-Estrada, M.E.; Pontarollo, R.; Foldvari, M.J.; Babiuk, S.; Baca-Estrada, M.E.; Foldvari, M.; Storms, M.; Rabussay, D.; Widera, G.; Babiuk, L.A. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine, 2002, 20, 3399-3408.
113. Delepine, P.; Guillaume, C.; Floch, V.; Loisel, S.; Yaouanc, J.; Clement, J.; Des Abbayes, H.; Ferec, C. Cationic phosphonolipids as nonviral vectors: in-vitro and in-vivo applications J. Pharm. Sci., 2000, 89, 629-638.
114. Heller, L.C.; Coppola, D. Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Ther., 2002, 9, 1321-1325.
115. Yamashita, Y.; Shimada, M.; Tachibana, K.; Harimoto, N.; Tsujita, E.; Shirabe, K.; Miyazaki, J.; Sugimachi, K. In vivo gene transfer into muscle via electro-sonoporation. Hum. Gene Ther., 2002, 13, 2079-2084. (Pubitemid 35417352)
116. Cemazar, M.; Sersa, G.; Wilson, J.; Tozer, G.M.; Hart, S.L.; Grosel, A.; Dachs, G.U. Effective gene transfer to solid tumors using different non-viral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther., 2002, 9, 399-406.
117. Neumann, E.; Rosenheck, K. Permeability changes induced by electric impulses in vescicular membrane. J. Membr. Biol., 1972, 10, 279-290.
118. Crowley, J.M. Electrical breakdown of biomolecular lipid membranes as an electromechanical instability. Biophy. J., 1973, 13, 711-724.
119. Zimmermann, U.; Vienken, J.; Pilwat, G. Dielectric breakdown of cell membranes. Biophys. J., 1974, l14, 881-899.
120. Weaver, J.C. Electroporation of cells and tissues. IEEE Trans. Plasma Sci., 2000, 28, 24-33.
121. Al-Sakere, B.A. ; Andre, F. ; Bernat, C. ; Connault, F. ; Opolon, P. ; Davalos, R. ; Rubinsky, B. ; Mir, L. Tumor ablation with irreversible electroporation. PLoS One, 2007, 2, e1135.
122. Ichor's TriGrid System. FDA approves phase I clinical trial using Ichor's TriGrid System and DNA vaccine for melanoma developed at Sloan-Kettering. May17, http://www.ichorms.com/pressreleases.shtml. accessed on august 2007
123. Regnier, V. ; Tahiri, A. ; Andre, N. ; Lemaitre, M. ; Le Doan, T. ; Preat, V. Electroporation-mediated delivery of 3-protected phosphodiester oligodeoxynucleotides to the skin. J. Control. Release, 2000, 67, 337-346. (Pubitemid 30303846)
124. Tokudome, Y.; Sugibayashi, K. The effects of calcium chloride and sodium chloride on the electroporation-mediated skin permeation of fluorescein isothiocyanate (FITC)-dextrans in vitro. Biol. Pharm. Bull., 2003, 26, 1508-1510. (Pubitemid 41685411)
125. Liu, H.; Li, S.; Pan, W.; Wang, Y.; Han, F.; Yao, H. Investigation into the potential of low-frequency ultrasound facilitated topical delivery of Cyclosporin A. Int. J. Pharm., 2006, 26, 32-38. (Pubitemid 44647744)
126. Zhang, L.; Hofmann, G. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications. US Pat., 2005, 6,947,791.
127. Riviere, J.E., Moteiro-Riviere, N.A., Rogers, R.A., Bommannan, D.; Tamada, J.A.; Potts, P.O. Pulsatile transdermal delivery of LHRH using electroporation: drug delivery and skin toxicology. J. Control. Release, 1995, 36, 229-233.
128. Chang, S.L.; Hofmann, G.A.; Zhang, L.; Deftos, L.J.; Banga, A.K. The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. J. Control. Release, 2000, 66, 127-133. (Pubitemid 30160851)
129. Daud, A.I.; DeConti, R.C.; Andrews, S.; Urbas, P.; Riker, A.I.; Sondak, V.K.; Munster, P.N.; Sullivan, D.M.; Ugen, K.E.; Messina, J.L.; Heller, R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol., 2008, 26, 5896-5903.
130. Marti, G.P.; Mohebi, P.; Liu, L.; Wang, J.; Miyashita, T.; Harmon, J.W. KGF-1 for wound healing in animal models. Methods Mol. Biol., 2008, 423, 383-391.
131. Wang, H.Y.; Lu, C. Microfluidic electroporation for delivery of small molecules and genes into cells using a common DC power supply. Biotechnol. Bioeng., 2008, 100, 579-586 (Pubitemid 351792933)
132. Babiuk, S.; Tsang, C.; van Drunen Littel-van den Hurk, S.; Babiuk, L.A.; Griebel, P.J.A. Single HBsAg DNA vaccination in combination with electroporation elicits long-term antibody responses in sheep. Bioelectrochemistry, 2007, 70, 269-274.
133. Hirao L.A.; Wu. L.; Khan, A.S.; Hokey, D.A.; Yan, J.; Dai, A.; Betts, M.R.; Draghia-Akli, R.; Weiner, D.B. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine, 2008, 26, 3112-3120
134. van Drunen Littel-van den Hurk, S.; Luxembourg, A.; Ellefsen, B.; Wilson, D.; Ubach, A.; Hannaman, D.; van den Hurk, J.V. Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle. Vaccine, 2008, 26, 5503-5509.
135. Medi, B.M.; Hoselton, S.; Marepalli, R.B.; Singh, J. Skin targeted DNA vaccine delivery using electroporation in rabbits. I: efficacy. Int. J. Pharm., 2005, 294, 53-63. (Pubitemid 40462322)
136. Lee, W.R.; Shen, S.C.; Fang, C.L.; Zhuo, R.Z.; Fang, J.Y. Topical delivery of methotrexate via skin pretreated with physical enhancement techniques: low-fluence erbium:YAG laser and electroporation. Lasers Surg. Med., 2008, 40, 468-476.
137. Wang, S.; Kara, M.; Krishnan, T.R. Transdermal delivery of cyclosporin-A using electroporation. J. Control. Release, 1998, 50, 61-70. (Pubitemid 28044101)
138. Denet, A.R.; Ucakar, B.; Préat, V. Transdermal delivery of timolol and atenolol using electroporation and iontophoresis in combination: a mechanistic approach. Pharm. Res., 2003, 20, 1946-1951 (Pubitemid 38005525)
139. Sung, K.C.; Fang, J.Y.; Wang, J.J.; Hu, O.Y. Transdermal delivery of nalbuphine and its prodrugs by electroporation. Eur. J. Pharm. Sci., 2003, 18, 63-70. (Pubitemid 36120556)
140. Fang, J.Y.; Sung, K.C.; Wang, J.J.; Chu, C.C.; Chen, K.T. The effects of iontophoresis and electroporation on transdermal delivery of buprenorphine from solutions and hydrogels. J. Pharm. Pharmacol., 2002, 54, 1329-1337.
141. Conjeevaram, R.; Banga, A.K.; Zhang, L. Electrically modulated transdermal delivery of fentanyl. Pharm. Res., 2002, 19, 440-444. (Pubitemid 34408942)
142. Wallace, M.S.; Ridgeway, B.; Jun, E.; Schulteis, G.; Rabussay, D.; Zhang, L. Topical delivery of lidocaine in healthy volunteers by electroporation, electroincorporation, or iontophoresis: an evaluation of skin anesthesia. Reg. Anesth. Pain Med., 2001, 26, 229-238. (Pubitemid 32479195)
143. Rowland, C.A.; Chilcott, R.P. The electrostability and electrically assisted delivery of an organophosphate pretreatment (physostigmine) across human skin in vitro. J. Control. Release, 2000, 68, 157-166.
144. Jadoul, A.; Lecouturier, N.; Mesens, J.; Caers, W.; Préat, V. Transdermal alniditan delivery by skin electroporation. J. Control. Release., 1998, 54, 265-272. (Pubitemid 28412657)
145. Pliquett, U,; Weaver, J.C. Feasibility of an electrode-reservoir device for transdermal drug delivery by noninvasive skin electroporation. IEEE Trans. Biomed. Eng., 2007, 54, 536-538
146. Fang, J.Y.; Hung, C.F.; Hwang, T.L.; Wong, W.W. Transdermal delivery of tea catechins by electrically assisted methods. Skin Pharmacol. Physiol., 2006, 19, 28-37.
147. Fang, J.Y.; Lee, W.R.; Shen, S.C.; Fang, Y.P.; Hu, C.H.; Enhancement of topical 5-aminolaevulinic acid delivery by erbium: YAG laser and microdermabrasion: a comparison with iontophoresis and electroporation. Br. J. Dermatol., 2004, 151, 132-140.
148. Essa, E.A.; Bonner, M.C.; Barry, B.W. Electrically assisted skin delivery of liposomal estradiol; phospholipid as damage retardant. J. Control. Release, 2004, 95, 535-546.